Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7465357 | 0.93 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL1863293 | 0.77 | CYP2A6 (0.66) | CYP2A6MRGPRX4OPRM1OPRK1 | |
| SCHEMBL29469368 | 0.77 | CYP2A6 (0.66) | CYP2A6MRGPRX4OPRM1OPRK1 | |
| SCHEMBL10230281 | 0.73 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL507426 | 0.73 | CYP2A6 (0.71) | CYP2A6MRGPRX4OPRM1OPRK1 | |
| SCHEMBL8058490 | 0.73 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL3150204 | 0.73 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL154793 | 0.73 | CYP2A6 (0.47) | CYP2A6MRGPRX4OPRM1OPRK1 | |
| SCHEMBL3145920 | 0.73 | MRGPRX4 (0.43) | CYP2A6MRGPRX4OPRM1OPRK1PSEN1 | |
| SCHEMBL6399446 | 0.72 | CYP2A6 (0.54) | CYP2A6OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | CYP2A6 392/4885MRGPRX4 2978/4885OPRM1 1101/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | CYP2A6 552/4885MRGPRX4 3157/4885OPRM1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.